研究者詳細 - 座間味　義人

論文 - 座間味　義人

分割表示 340 件中 261 - 280 件目／全件表示 >>

Nerve Growth Factor Facilitates the Innervation of Perivascular Nerves in Tumor-Derived Neovasculature in the Mouse Cornea 査読

Yoko Sone, Shingo Takatori, Eiko Ochi, Yoshito Zamami, Akiko Matsuyama, Satoko Fukuhara, Mitsuhiro Goda, Yoshihisa Kitamura, Hiromu Kawasaki

PHARMACOLOGY 99 ( 1-2 ) 57 - 66 2017年

Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells. 査読国際誌

Ken Konaka, Kota Moriyama, Takumi Sakurada, Naoto Okada, Masaki Imanishi, Yoshito Zamami, Kazuyoshi Kawazoe, Shuji Fushitani, Keisuke Ishizawa

Journal of pharmaceutical health care and sciences 3 20 - 20 2017年

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent paclitaxel, can force the premature discontinuation of treatment. As some kampo practitioners have suggested that it may be possible to counteract such side effects, we analyzed the effects of Kamishoyosan, Shakuyakukanzoto, and Goshajinkigan in an in vitro model of paclitaxel-induced peripheral neuropathy. METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo. We also compared phosphorylation of extracellular signal-regulated kinase (Erk)1/2 and Akt via Western blot analysis. About effect of kampo to anticancer efficacy, we confirmed cell cytotoxicity in A549 cells using MTT assay. RESULTS: Addition of Kamishoyosan or Shakuyakukanzoto, but not Goshajinkigan, significantly improved neurite length and GAP-43 and NF-L levels from paclitaxel-treated PC12 cells, relative to those of only NGF-treated PC12 cells. The promoting effect of Kamishoyosan and Shakuyakukanzoto in neurite outgrowth is confirmed when NGF promoted neurite outgrowth, and it was inhibited partially when Erk1/2 and Akt were blocked by Erk1/2 inhibitor or Akt inhibitor alone. Furthermore, neurite outgrowth induced by TJ24 and TJ68 was inhibited more strongly when Erk1/2 inhibitor and Akt inhibitor were treated at the same time. NGF with Kamishoyosan or Shakuyakukanzoto promoted the proportion of phosphorylated Erk1/2 and phosphorylated Akt compare with NGF only. On the other hand, Kamishoyosan or Shakuyakukanzoto didn't influence cytotoxicity of paclitaxel in A549 cells. CONCLUSIONS: Kamishoyosan or Shakuyakukanzoto promotes neurite outgrowth with NGF via increasing the proportion of phosphorylated Erk1/2 and phosphorylated Akt in PC12 cells. The effect applies to recovery from paclitaxel-induced axonal involvement and might promote recovery from paclitaxel-induced neuropathy without influence of anticancer effect of paclitaxel.

DOI： 10.1186/s40780-017-0090-y

PubMed

researchmap

[Drug Repositioning Research Utilizing a Large-scale Medical Claims Database to Improve Survival Rates after Cardiopulmonary Arrest]. 査読

Yoshito Zamami, Takahiro Niimura, Kenshi Takechi, Masaki Imanishi, Toshihiro Koyama, Keisuke Ishizawa

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 137 ( 12 ) 1439 - 1442 2017年

記述言語：日本語掲載種別：研究論文（学術雑誌）

Approximately 100000 people suffer cardiopulmonary arrest in Japan every year, and the aging of society means that this number is expected to increase. Worldwide, approximately 100 million develop cardiac arrest annually, making it an international issue. Although survival has improved thanks to advances in cardiopulmonary resuscitation, there is a high rate of postresuscitation encephalopathy after the return of spontaneous circulation, and the proportion of patients who can return to normal life is extremely low. Treatment for postresuscitation encephalopathy is long term, and if sequelae persist then nursing care is required, causing immeasurable economic burdens as a result of ballooning medical costs. As at present there is no drug treatment to improve postresuscitation encephalopathy as a complication of cardiopulmonary arrest, the development of novel drug treatments is desirable. In recent years, new efficacy for existing drugs used in the clinical setting has been discovered, and drug repositioning has been proposed as a strategy for developing those drugs as therapeutic agents for different diseases. This review describes a large-scale database study carried out following a discovery strategy for drug repositioning with the objective of improving survival rates after cardiopulmonary arrest and discusses future repositioning prospects.

DOI： 10.1248/yakushi.17-00139-3

PubMed

researchmap

Pharmacological approach for drug repositioning against cardiorenal diseases. 査読

Yoshito Zamami, Masaki Imanishi, Kenshi Takechi, Keisuke Ishizawa

The journal of medical investigation : JMI 64 ( 3.4 ) 197 - 201 2017年

記述言語：英語掲載種別：研究論文（学術雑誌）

New applications of approved clinically used drugs are being discovered. Drug repositioning is a proposed strategy for developing these drugs as therapeutic agents for different diseases. Currently, approximately 2000 drugs are used in Japan. However, the compound targets and pathways involved in the pharmacological actions of 70-80% of these drugs have not been adequately clarified. Pharmacological examination of approved drugs is an important task in drug repositioning and vital for improving drug development efficiency. This review reports that angiotensin II type 1 receptor blockers show receptor-independent effects against reactive oxygen species generation in renal cells. Additionally, nitrosonifedipine has an antioxidative effect and protects endothelial cells against oxidative stress, and pioglitazone has multiple effects that improve dysfunctions in vascular control regulated by adrenergic and calcitonin gene-related peptide-containing nerves in animal models of diabetes. These data suggest that some approved drugs could be useful for treating cardiorenal diseases. Since cardiorenal diseases are likely to have chronic pathological conditions and require chronic drug administration, highly safe drugs are needed. Compared to newly developed drugs, drug repositioning of approved drugs with safety information is considered a particularly useful technique for searching new treatments for cardiorenal diseases. J. Med. Invest. 64: 197-201, August, 2017.

DOI： 10.2152/jmi.64.197

PubMed

researchmap

Drug-administering persons’ exposure to oral anticancer drugs to be administered through a tube 査読

Masahiro Murakami, Satoko Katsuragi, Masako Ohno, Makoto Shigematsu, Ayumi Kishi, Yoshito Zamami, Fusao Komada, Naomi Kurata, Manabu Amano

Asian Journal of Pharmaceutical and Clinical Research 9 ( No.3 ) 316 - 319 2016年12月

Evaluation of pharmaceutical lifesaving skills training oriented pharmaceutical intervention. 査読国際誌

Zamami Y, Imai T, Imanishi M, Takechi K, Shiraishi N, Koyama T, Sagara H, Shiino Y, Sendo T, Ishizawa K

Journal of pharmaceutical health care and sciences 2 ( 1 ) 21 - 21 2016年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

Our high-performance patient simulator-based lifesaving skills training program not only increased the participants' understanding of the training content but also increased their confidence in their ability to perform pharmaceutical interventions. Therefore, the pharmaceutical lifesaving skills training program we developed will contribute to the education of emergency care pharmacists who can perform pharmaceutical interventions for emergency patients.

DOI： 10.1186/s40780-016-0054-7

PubMed

researchmap

Possibility of Pharmacist in Emergency Medical Care: To Bring Up a Familiar Pharmacist for Emergency Care by Fusing Clinical Pharmacist Activity and University Education Foreword 査読

Yoshito Zamami, Toshihiro Koyama, Hironori Nakura, Shuichi Enomoto

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 136 ( 7 ) 965 - 965 2016年7月

Pharmaceutical Education Focused on Pharmacotherapy in Emergency Medical Care 査読

Yoshito Zamami, Toshihiro Koyama, Toru Imai, Akane Takemoto, Hidenori Sagara, Toshiaki Sendo, Hironori Nakura

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 136 ( 7 ) 987 - 991 2016年7月

Vascular responses to compound 48/80 in rat mesenteric vascular beds 査読

Honghua Jin, Zhen Li, Shingo Takatori, Toshihiro Koyama, Xin Jin, Yoshito Zamami, Hiromu Kawasaki, Pengyuan Sun

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY 94 ( 6 ) 620 - 626 2016年6月

脳梗塞患者における発症前後の薬物療法と副作用発現状況の調査

安尾哲郎, 座間味義人, 名倉弘哲

日本臨床救急医学会雑誌 19 ( 2 ) 425 - 425 2016年4月

Muscarinic acetylcholine receptor M1 and M3 subtypes mediate acetylcholine-induced endothelium-independent vasodilatation in rat mesenteric arteries 査読

Panot Tangsucharit, Shingo Takatori, Yoshito Zamami, Mitsuhiro Goda, Poungrat Pakdeechote, Hiromu Kawasaki, Fusako Takayama

JOURNAL OF PHARMACOLOGICAL SCIENCES 130 ( 1 ) 24 - 32 2016年1月

Risk factor of acute renal failure induced by edaravone in patients with cerebrovascular disorder 査読

座間味義人, 相良英憲, 萱野由佳, 小山敏広, 白石奈緒子, 江角悟, 川豊世武, 千堂年昭, 氏家良人, 名倉弘哲

日本臨床救急医学会雑誌 Vol.19 ( No.3 ) 461 - 465 2016年

記述言語：日本語掲載種別：研究論文（学術雑誌）

エダラボンを用いた治療は患者の神経学的予後を改善する一方，急性腎障害発現のリスクがあると報告されている．本研究はエダラボン投与による急性腎障害発現を予防するために，エダラボン投与時の患者背景から危険因子を解析することを目的とした．岡山大学病院においてエダラボンが投与された患者を対象に，患者基本情報およびエダラボン投与情報，血液検査結果を電子カルテより遡及的に調査した．調査データから単変量解析を実施し，抽出した因子を用いて二項ロジスティック回帰分析を行った結果，感染症の併発が，エダラボンによる急性腎障害発現の有意な危険因子(予測因子)であることが示唆された．したがって，感染症の所見がある患者にエダラボンを投与する際は，急性腎障害発現に留意する必要がある．

DOI： 10.11240/jsem.19.461

CiNii Article

researchmap

光に対して不安定な薬剤を経管投与する際の有用な投与法の開発査読

座間味義人, 江角悟, 相良英憲, 槙田崇志, 天野学, 安藤哲信, 名和秀起, 北村佳久, 千堂年昭, 名倉弘哲

医学と薬学 Vol.73 ( 4 ) 433 - 438 2016年